Gotowa bibliografia na temat „Curcumine – Analogues”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Curcumine – Analogues”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Curcumine – Analogues"
Al-Asadi, Ali M., Salah S. Al-Luaibi, Basil A. Saleh, Mohammed A. Baashen i Gamal A. El-Hiti. "Antioxidant Properties of Curcumin Analogues to Inhibit Thermal Degradation of Low-Density Polyethylene: Experimental and DFT Study". Journal of Chemistry 2022 (20.06.2022): 1–6. http://dx.doi.org/10.1155/2022/5391296.
Pełny tekst źródłaNocito, Marta Claudia, Arianna De Luca, Francesca Prestia, Paola Avena, Davide La Padula, Lucia Zavaglia, Rosa Sirianni i in. "Antitumoral Activities of Curcumin and Recent Advances to ImProve Its Oral Bioavailability". Biomedicines 9, nr 10 (14.10.2021): 1476. http://dx.doi.org/10.3390/biomedicines9101476.
Pełny tekst źródłaYi, Yau Xin, Anand Gaurav i Gabriel A. Akowuah. "Docking Studies of Curcumin and Analogues with Various Phosphodiesterase 4 Subtypes". Current Drug Discovery Technologies 17, nr 2 (19.06.2020): 248–60. http://dx.doi.org/10.2174/1570163815666181017091655.
Pełny tekst źródłaCheng, Yatian, Jian Zhang, Yan Shao, Yixiang Xu, Haixia Ge, Boyang Yu i Weiwei Wang. "Enzyme-Catalyzed Glycosylation of Curcumin and Its Analogues by Glycosyltransferases from Bacillus subtilis ATCC 6633". Catalysts 9, nr 9 (29.08.2019): 734. http://dx.doi.org/10.3390/catal9090734.
Pełny tekst źródłaMuhammad, Imran, Nadeem Muhammad, Khan Muhammad Asif, Ahmed Sheraz, Imran Ali, Amir Rai Muhammad, Arshad Muhammad Umair i in. "Curcumin and its allied analogues: epigenetic and health perspectives – a review". Czech Journal of Food Sciences 35, No. 4 (30.08.2017): 285–310. http://dx.doi.org/10.17221/584/2015-cjfs.
Pełny tekst źródłaAthipornchai, Anan, Nattisa Niyomtham, Wachirachai Pabuprapap, Vachiraporn Ajavakom, Maria Duca, Stéphane Azoulay i Apichart Suksamrarn. "Potent Tyrosinase Inhibitory Activity of Curcuminoid Analogues and Inhibition Kinetics Studies". Cosmetics 8, nr 2 (4.05.2021): 35. http://dx.doi.org/10.3390/cosmetics8020035.
Pełny tekst źródłaMorais de Lima, Ednilza, Gabriel Antônio dos Santos, Khaled Hayek, José Jardes Da Gama Bitencourt i Carolina Passarelli Gonçalves. "Biossíntese Dirigida pelo Precursor de Curcumina pela Curcuma longa L." Ensaios e Ciência C Biológicas Agrárias e da Saúde 25, nr 3 (29.09.2021): 357–60. http://dx.doi.org/10.17921/1415-6938.2021v25n3p357-360.
Pełny tekst źródłaR, Thirumalaisamy. "Comparative Anti–Alzheimer’s Potential Evaluation of Curcumin and Curcumin Analogues obtained from ZINC Database: An in-Silico Validation". TEXILA INTERNATIONAL JOURNAL OF PUBLIC HEALTH 9, nr 4 (28.12.2021): 269–83. http://dx.doi.org/10.21522/tijph.2013.09.04.art023.
Pełny tekst źródłaAhsan, Mohamed Jawed, Kavita Choudhary, Amena Ali, Abuzer Ali, Faizul Azam, Atiah H. Almalki, Eman Y. Santali, Md Afroz Bakht, Abu Tahir i Salahuddin. "Synthesis, DFT Analyses, Antiproliferative Activity, and Molecular Docking Studies of Curcumin Analogues". Plants 11, nr 21 (25.10.2022): 2835. http://dx.doi.org/10.3390/plants11212835.
Pełny tekst źródłaChen, Jian, Linlin Zhang, Yilai Shu, Liping Chen, Min Zhu, Song Yao, Jiabing Wang i in. "Curcumin Analogue CA15 Exhibits Anticancer Effects on HEp-2 Cells via Targeting NF-κB". BioMed Research International 2017 (2017): 1–10. http://dx.doi.org/10.1155/2017/4751260.
Pełny tekst źródłaRozprawy doktorskie na temat "Curcumine – Analogues"
Jourdan, Jean-Pierre. "Conception, synthèse et évaluation biologique de nouveaux analogues de la curcumine : potentiels agents pléiotropes d'intérêt thérapeutique dans la maladie d'Alzheimer". Caen, 2015. http://www.theses.fr/2015CAEN4012.
Pełny tekst źródłaAlzheimer's disease, the most common form of elderly dementia in the world, is a progressive, chronic, degenerative and irreversible disease. They are many pathophysiological causes of dementia, among them there may be mentioned β-aggregation of amyloid peptides, tau protein hyperphosphorylation, neuronal inflammation and oxidative stress. A recently developed therapeutic approach to modify the evolution of this multifactorial disease is the design of multi-target directed ligands. In the nature, there are molecules with such functions like curcumin. It’s a natural polyphenol extracted from the plant Curcuma longa L. And it can be considered as an active product useful in the treatment of Alzheimer's disease because of its inhibitory properties of β-amyloid aggregation, antioxidant and inflammatory inhibition activities. However, it suffers from poor bioavailability and can’t be used in therapy. That's why we designed novel curcumin analogs in pyrrolizinone and aminoindanone series as potential multi-target ligands potentially useful in the treatment of Alzheimer's disease. In this manuscript, is described the drug design approach combining medicinal chemistry, molecular modeling and biological assessments leading to these analogues. Finally, a preliminary drugability study of the newly synthesized compounds is presented
Pecourneau, Jérémy. "Réponses photoinduites d'analogue biomimétique de la cyclocurcumine : vers des thérapies assistées par la lumière". Electronic Thesis or Diss., Université de Lorraine, 2022. http://www.theses.fr/2022LORR0205.
Pełny tekst źródłaBeyond photodynamic therapy (PDT), there are several light-assisted therapeutic alternatives, including photothermal therapy (PTT) and photoisomerization, whose mechanical action would induce cellular damage within the membranes. Also, molecules able to simultaneously absorb two photons would overcome the need for high energy excitation per photon while maintaining sufficient tissue penetration. In this context, we were interested in designing and studying biomimetic analogues of cyclocurcumin (CC), a natural E/Z photoswitch. Guided by molecular modeling, those novel donor-acceptor compounds were structurally designed to increase the effective two-photon absorption cross section (σ2).First, we synthesized two classes of CC analogues bearing acceptor (oxo and malonitrile) and donor (hydroxy, alkoxy and amine) groups as well as a PEG arm to increase their hydrophilicity. Free in solution, the oxo derivatives show a reversible photoinduced isomerization, without any thermal isomerization in the dark, whereas the malonitrile derivatives do not photoswitch but undergo a vibrational relaxation. This is leading to a temperature increase, of interest in photothermal therapy. Finally, confined in a lipidic environment (liposomes bilayers and Langmuir monolayers), the direct E→Z isomerization kinetics of oxo compounds is strongly slowed down and no Z→E back isomerization is observed. Those compounds also showed a certain efficiency to disrupt membrane fluidity, more or less pronounced depending on the form, Z or E, the length of the alkoxy chain or the presence of the PEG unit. The malonitrile derivatives exhibit a diminished photothermal effect in lipid bilayers after several irradiation cycles.Taken together, this study is a proof of concept for the potential of photoinduced responses of cyclocurcumin analogs for disruption of membrane fluidity towards potential use in vivo
Schmitt, Bonell. "Curcumin analogues as ligands for Re (I) and (V)". Thesis, Nelson Mandela Metropolitan University, 2012. http://hdl.handle.net/10948/d1020975.
Pełny tekst źródłaSouza, Nayane de. "Efeitos citotóxicos do DM-1 em células de melanoma resistentes a um inibidor de BRAF e na expressão de metaloproteinases". Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/9/9143/tde-06122017-105135/.
Pełny tekst źródłaMalignant melanoma is the most aggressive cancer and the BRAF V600E mutation is the most frequent among patients. Vemurafenib was the first specific inhibitor for this mutation approved by Food and Drug Administration. Therefore around six months later there is relapse and overcoming it is still a challenge. Curcumin is a turmeric and it has been deeply researched because of its anti-inflammatory and antitumoral effects. However the low stability limits its use, therefore, encouraged the investigation of analogues capable to be efficient and commercialized. DM-1 is a monoketone curcumin analog and it showed antitumoral effects in vitro and in vivo in previous studies The aim of this project was to evaluate the cytotoxical effects of DM-1 for vemurafenib responsive (naïve) and resistant melanoma cells, as well as metalloproteinases modulation. Melanoma cells were treated with different DM-1 concentrations, and this compound was cytotoxic for responsive and resistant cell lines, besides inducing G1/G0 cell cycle arrest and reducing the number of colonies, nonetheless it was not selective in assays performed with melanocytes and fibroblasts. Subtoxic treatment of those cells modulated important MMPs in the cell invasion process. DM-1 reduced metalloproteinases -1, -2 and -9 (MMP-1,-2 and -9) in a quantification assay, and MMP-2 and -9 activities by zymography in a cell-dependent way. Negative modulations of MMP inhibitor TIMP-2 and MMP-14 for SKMEL-28 naïve were associated with MMP-2 and -9 reduced activities, whereas positive modulations for SKMEL-19 naïve were correlated to MMP-2 increase. Furthermore, this compound reduced migration of those cells and endothelial cell tube formation.
Al-shdifat, Laith Mohammad Hilal. "Approaches to Enhancing the Properties of a Promising Curcumin Analogue". Thesis, The University of Sydney, 2021. https://hdl.handle.net/2123/25786.
Pełny tekst źródłaAbdelhamid, Dalia. "Natural Products as Lead Compounds for Drug Development. Part I: Synthesis and Biological Activity of a Structurally Diverse Library of Curcumin Analogues. Part II: Synthesis of Novel Sterol Natural Products and Related Analogues as Antileishmanial Ag". The Ohio State University, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=osu1299685922.
Pełny tekst źródłaTedesco, Serena. "Activation phenotypes of human monocyte-derived macrophages: methodological approaches and pharmacological modulation by curcumin analogues". Doctoral thesis, Università degli studi di Padova, 2016. http://hdl.handle.net/11577/3427229.
Pełny tekst źródłaIn condizioni normali i macrofagi sono i responsabili della risposta immunitaria e della difesa dell’ospite per mantenere l’omeostasi tissutale. In seguito a stimoli presenti nel microambiente, i macrofagi possono attivarsi, andando incontro a uno switch morfologico e funzionale. L’attivazione di queste cellule non è un processo “tutto o nulla” ma piuttosto un continuum caratterizzato da un ampio spettro di fenotipi molecolari e funzionali, i cui estremi sono rappresentati dal fenotipo definito “classico” o M1, con un profilo pro-infiammatorio, e da quello “alternativo” o M2, anti-infiammatorio e protettivo. La possibilità di promuovere un fenotipo macrofagico protettivo sta diventando un obiettivo terapeutico nel trattamento delle condizioni infiammatorie e l’identificazione di fattori che regolano l’attivazione cellulare è attualmente un’area di ricerca molto attiva. La maggior parte degli studi in questo ambito sono stati condotti utilizzando culture primarie di macrofagi di topo o linee cellulari; inoltre, i vari laboratori usano protocolli diversi di isolamento/differenziamento dei monociti e marcatori diversi di attivazione. Inoltre, il controllo farmacologico dell’attivazione macrofagica non è ancora stato indagato sufficientemente. Una serie di composti naturali e sintetici, ad esempio il calcone e la curcumina, il principale componente attivo della Curcuma longa (pianta nota per effetti anti-ossidanti, anti-microbici, anti-tumorali e anti-infiammatori) hanno dimostrato un effetto sulla funzione dei macrofagi, agendo attraverso diversi meccanismi farmacologici, ad esempio interferendo con il signaling del TLR4. Sulla base di queste premesse, gli scopi specifici di questo lavoro di tesi erano: a) testare un modello cellulare e un protocollo di differenziamento diverso da quello spontaneo, in particolare la linea cellulare monocitaria THP-1 e il differenziamento in presenza di CSF-1; b) determinare il profilo delle citochine presenti nel terreno di coltura e c) determinare la modulazione dei marcatori dei fenotipi di attivazione da parte di agenti farmacologici, in particolare da derivati di sintesi della curcumina, noti per la loro capacità di modulare l’attivazione di cellule murine di microglia attraverso la riduzione della produzione e rilascio di mediatori pro-infiammatori. I macrofagi sono stati differenziati a partire dai linfo-monociti umani isolati tramite gradiente di densità e coltivati in terreno RPMI + 10% FBS con aggiunta di CSF-1 per 6 giorni, ottenendo così macrofagi in condizioni basali (M0). Il fenotipo classico (M1) e il fenotipo alternativo (M2) sono stati ottenuti incubando i macrofagi M0 rispettivamente con 0.1-1 μg/ml LPS e IL-4 20 ng/ml + IL-13 5 ng/ml, in presenza o assenza di analoghi della curcumina, desametazone o CLI095, un inibitore del dominio intracellulare del TLR4 (questi ultimi utilizzati come composti di riferimento). I fenotipi macrofagici sono stati determinati tramite citofluorimetria utilizzando specifici anticorpi legati a fluorofori. L’espressione genica è stata valutata tramite qRT-PCR. La composizione dei terreni condizionati (macrophage conditioned media, MCM) è stata valutata con la tecnologia Luminex. Gli analoghi della curcumina sono stati gentilmente forniti dalla Prof.ssa Federica Belluti (Università di Bologna). In seguito a polarizzazione per 24 h con IL-4/IL-13 abbiamo osservato un aumento dell’espressione dei marcatori M2 rispetto a M0. Per quanto riguarda l’espressione genica di macrofagi differenziati con CSF-1, come atteso, i macrofagi M1 dopo 6 o 48h presentavano livelli superiori di mRNA per TNF-α e IL-1β rispetto a M0. L’aumento dell’mRNA era più marcato dopo 48 h per tutti i geni tranne TNF-α, che raggiungeva il picco a 6h. L’mRNA della citochina anti-infiammatoria IL-10 inaspettatamente era più espresso nei macrofagi M1 rispetto a M2 e raggiungeva il picco dopo 6 h. Rispetto a M0, l’MCM M2 era caratterizzato da alti livelli di citochine anti-infiammatorie tra le quali CCL22 e IL-4. Al contrario, l’MCM M1 presentava livelli elevati di IL-1α, IL-1β, IL-6, IL-8, MCP-1, VEGF e TNF-α. Il pre-trattamento con l’analogo della curcumina GG9 e il controllo positivo CLI095 ha prevenuto l’aumento indotto da LPS del marcatore M1 CD80. Un effetto simile è mantenuto anche sulla frazione di cellule a doppia marcatura CD80+/CCR2+. Al contrario del desametazone, che aumenta la percentuale di cellule CD163+ (M2), il GG9 non ha modulato i marcatori M2. Il trattamento con GG9 ha bloccato in maniera significativa la produzione di IL-1β valutata come citochina cell-bound, nel lisato cellulare o rilasciata nel terreno di coltura. Al contrario, l’analogo GG6 non ha modificato i livelli di IL-1β intra- ed extra-cellulare. Per indagare più nel dettaglio le vie di segnale coinvolte nell’attivazione di queste cellule, abbiamo effettuato analisi Western Blot di fattori coinvolti nella via di segnale di NF-κB. L’attivazione con LPS ha ridotto significativamente l’espressione relativa di IκB-α. Curcumina, GG6 e CLI095 hanno riportato IκB-α ai livelli di controllo, a differenza del GG9 che non modificava significativamente l’espressione di questa proteina. Pertanto, i macrofagi M1 ed M2 presentano specifici profili di attivazione genica e di marcatori di superficie che possono essere modulati in seguito a trattamento farmacologico con desametazone o analoghi della curcumina. Nel complesso, questi dati suggeriscono che protocolli di attivazione macrofagica possono avere un impatto sullo stato funzionale di queste cellule e sono fondamentali per definire nuove strategie di targeting farmacologico nei macrofagi umani.
SINGH, REETIKA. "COMPARATIVE ANALYSIS OF DIFFERENT CURCUMIN ANALOGUES TO INHIBIT TLR4 EXPRESSION IN BREAST CANCER- AN IN-SILICO STUDY". Thesis, DELHI TECHNOLOGICAL UNIVERSITY, 2021. http://dspace.dtu.ac.in:8080/jspui/handle/repository/18459.
Pełny tekst źródła"INVESTIGATING THE MASS SPECTROMETRIC BEHAVIOR OF NOVEL ANTINEOPLASTIC CURCUMIN ANALOGUES". Thesis, 2015. http://hdl.handle.net/10388/ETD-2015-01-1911.
Pełny tekst źródłaZe, Chen Chu, i 陳楚澤. "Xanthine Oxidase and α-Glucosidase Inhibition of Curcumin and Curcumin Analogs". Thesis, 2015. http://ndltd.ncl.edu.tw/handle/y83s8x.
Pełny tekst źródła輔仁大學
食品科學系碩士班
103
Curcumin is a constituent from root and stem of family Zingiberaceae and Araceae. It has been used as a natural colorant in food industry. Curcumin has a great value in food and medicine, and it has been reported that curcumin could inhibit the activities of xanthine oxidase (XO) and α-glucosidase that make curcumin can be used for treatment of gout and diabetes. Chemical synthesis, which can change the structure of component, can enhance the activities, even create a new one. Therefore, the objective of this research is to evaluate the characterization of curcumin and its analogs as XO and α-glucosidase inhibitors. In this study, after screening XO and α-glucosidase inhibition, the components which have high inhibitory activities were calculated their half-maximal inhibitory concentration (IC50) and enzyme inhibitory kinetics. In order to calculating the inhibitory reaction constant, a docking algorithm simulates binding position between enzyme and inhibitors. The results showed that among all the curcumin and its analogs, CM-F had the strongest anti-oxidant activity with a half-maximal effective concentration (EC50) of 9.39 ± 0.16 μM, which was better than vitamin E (EC50=17.03 ± 0.09 μM). It also had a good XO inhibitory activity, and its IC50 value against XO was 6.14 ± 0.38 μM. The enzyme kinetic result showed it was competitive inhibition. As for α-glucosidase, CM-1 and CM-2 have good α-glucosidase inhibitory activities with the IC50 value of 21.06 ± 0.92 μM and 5.95 ± 0.09 μM, of which kinetic study indicates that both CM-1 and CM-2 are mix-competitive inhibitors on α-glucosidase. Furthermore, docking simulation showed there are 5 hydrogen bonds between XO and CM-F. However, only 1 and 2 hydrogen bonds involved in CM-1 and CM-2 binding to α-glucosidase, respectively. Accordingly, analogs of curcumin have the potentials using in the gout or diabetes patients.
Części książek na temat "Curcumine – Analogues"
Awad, H., U. Das, J. Dimmock i A. El-Aneed. "Tandem Mass Spectrometric Analysis of Novel Antineoplastic Curcumin Analogues". W Detection of Chemical, Biological, Radiological and Nuclear Agents for the Prevention of Terrorism, 223–31. Dordrecht: Springer Netherlands, 2014. http://dx.doi.org/10.1007/978-94-017-9238-7_15.
Pełny tekst źródłaRanjbar, Reza, Hossein Bagheri, Faezeh Ghasemi, Paul C. Guest i Amirhossein Sahebkar. "Effects of Curcumin and Its Analogues on Infectious Diseases". W Studies on Biomarkers and New Targets in Aging Research in Iran, 75–101. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-56153-6_5.
Pełny tekst źródłaHaldar, Animeshchandra G. M., Kanhaiya M. Dadure i Debarshi Kar Mahapatra. "Recent Advancements of Curcumin Analogs and Curcumin Formulations in Context to Modern Pharmacotherapeutics Perspectives". W Applied Pharmaceutical Practice and Nutraceuticals, 121–45. First edition.: Apple Academic Press, 2021. http://dx.doi.org/10.1201/9781003054894-9.
Pełny tekst źródłaGinnebaugh, Kevin R., Aamir Ahmad i Fazlul H. Sarkar. "Updates on the Promising Anticancer Activity of CDF, a Synthetic Curcumin Analogue". W Critical Dietary Factors in Cancer Chemoprevention, 3–12. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-21461-0_1.
Pełny tekst źródłaYang, Jennifer, i Gregory B. Lesinski. "Curcumin Analogs as Inhibitors of the Jak-STAT Signal Transduction Pathway". W Novel Apoptotic Regulators in Carcinogenesis, 247–66. Dordrecht: Springer Netherlands, 2012. http://dx.doi.org/10.1007/978-94-007-4917-7_10.
Pełny tekst źródłaWei, Dangheng, Yanghui Liu, Xiaoying Jia, Fengxia Guo i Jiangzhang Wu. "A novel synthetic analogue of curcumin, B7, inhibits inflammatory factors expression in H2O2 induced endothelial cells". W IFMBE Proceedings, 636–38. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-29305-4_166.
Pełny tekst źródłaShioorkar, Mahesh G., i Omprakash S. Chavan. "ENVIRONMENTALLY BENIGN MICROWAVE ASSISTED CATALYST FREE SYNTHESIS OF CURCUMIN PYRIMIDINONE AND THIOPYRIMIDINONE ANALOGUES". W Futuristic Trends in Chemical, Material Sciences & Nano Technology Volume 2 Book 12, 197–207. Iterative International Publishers, Selfypage Developers Pvt Ltd, 2023. http://dx.doi.org/10.58532/v2bs12p2ch4.
Pełny tekst źródłaSivalingam, Nageswaran, Thennavan Ulaganathan, Ganshyam Jayakumar, Siddarth Venkatt, Aadhavan Balakumar i Sruthi Sritharan. "Unraveling the Chemistry of Curcumin for Colon Cancer Prevention and Treatment". W Multidisciplinary Applications of Natural Science for Drug Discovery and Integrative Medicine, 61–115. IGI Global, 2023. http://dx.doi.org/10.4018/978-1-6684-9463-9.ch003.
Pełny tekst źródłaGokhale, Kunal M., Chaitanya Walekar i Snehal Manje. "Novel Curcumin Analogues: Synthesis and Therapeutic Applications". W Current Overview on Pharmaceutical Science Vol. 5, 86–116. B P International (a part of SCIENCEDOMAIN International), 2023. http://dx.doi.org/10.9734/bpi/cops/v5/17813d.
Pełny tekst źródłaGupta, A. P., S. Khan, M. M. Manzoor, A. K. Yadav, G. Sharma, R. Anand i S. Gupta. "Anticancer Curcumin: Natural Analogues and Structure-Activity Relationship". W Studies in Natural Products Chemistry, 355–401. Elsevier, 2017. http://dx.doi.org/10.1016/b978-0-444-63929-5.00010-3.
Pełny tekst źródłaStreszczenia konferencji na temat "Curcumine – Analogues"
Nagaraju, Ganji Purnachandra, Shijun Zhu, Roberto Diaz, Mamoru Shoji i Bassel F. El-Rayes. "Abstract 3828: Potent curcumin analogues inhibit pancreatic cancer cell growth and angiogenesis". W Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3828.
Pełny tekst źródłaLeow, Pay Chin, Choon Pei Boon, Chong Yew Lee, Mei-Lin Go i Pui-Lai Rachel Ee. "Abstract 755: Design and synthesis of curcumin analogues as Wnt/β-catenin antagonists". W Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-755.
Pełny tekst źródłaKasinski, Andrea, Yuhong Du, Shala Thomas, Jing Zhao, Shi-Yong Sun, Fadlo Khuri, Chun-Yu Wang i in. "Abstract B106: Inhibition of IKKb and NFκB signaling by a novel curcumin analogue". W Abstracts: Frontiers in Cancer Prevention Research 2008. American Association for Cancer Research, 2008. http://dx.doi.org/10.1158/1940-6207.prev-08-b106.
Pełny tekst źródłaMardiana, L., B. Ardiansah, A. Septiarti, R. Bakri i G. Kosamagi. "Ultrasound-assisted synthesis of curcumin analogs promoted by activated chicken eggshells". W INTERNATIONAL SYMPOSIUM ON CURRENT PROGRESS IN MATHEMATICS AND SCIENCES 2016 (ISCPMS 2016): Proceedings of the 2nd International Symposium on Current Progress in Mathematics and Sciences 2016. Author(s), 2017. http://dx.doi.org/10.1063/1.4991200.
Pełny tekst źródłaPisano, Marina, Ilaria Sassu, Sara Cossu, Antonio Corrias, Valentina Nieddu, Mario Pescatori, Grazia Galleri i in. "Abstract 3804: Molecular changes induced by the curcumin biphenyl analogue D6 in melanoma cells". W Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3804.
Pełny tekst źródłaYadav, Babasaheb D., Sebastien Taurin, Lesley Larsen i Rhonda J. Rosengren. "Abstract 3556: New curcumin analogues are cytotoxic towards estrogen receptor negative human breast cancer cell lines". W Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-3556.
Pełny tekst źródłaBao, Bin, Shadan Ali, Dejuan Kong, Sanila H. Sarkar, Zhiwei Wang, Sanjeev Banerjee, Amro Aboukameel, Subhash Padhye, Philip A. Philp i Fazlul H. Sarkar. "Abstract 173: Targeted killing of cancer stem-like cells by a novel analogue of curcumin". W Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-173.
Pełny tekst źródłaPisano, Marina, Gabriella Pagnan, Maria Antonietta Dettori, Sara Cossu, Irene Caffa, Ilaria Sassu, Davide Fabbri i in. "Abstract B202: A new curcumin analogue compound endowed with strong antitumor activity against neuroectoderma‐derived cancers". W Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-b202.
Pełny tekst źródłaAmin, A. R. M. Ruhul, Michelle Lee, Mohammad A. Rahman, James R. Fuchs, Zhuo G. Chen i Dong M. Shin. "Abstract 5425: Potent curcumin analogue FLLL-22, but not natural curcumin, targets the DNA damage pathway for apoptosis in lung and head and neck cancer cells". W Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-5425.
Pełny tekst źródłaObara, Megumi, Shinobu Ohnuma, Eduardo E. Chufan, Masaharu Ishida, Katsuyoshi Kudoh, Norihiko Sugisawa, Hideo Ohtsuka i in. "Abstract 3242: Synthetic analogs of curcumin as modulators of multidrug resistance-linked ABC transporters". W Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-3242.
Pełny tekst źródła